Impact of the Sample Clauses

Impact of the. Radio Evolution towards 5G on the Transport Network We observe that, the transport network evolution to support 5G RAN has to cope with requirements in term of capacity, latency, Hops lengths, but also has to support different transport model, ranging from Backhaul, XHaul up to Fronthaul imposing stringent requirement as capacity and latency. Last but not least, even the transport network topology has to evolve from what is today, based on tree topology and few rings, to something closer to a full connected topology, the meshed network, managed from a central control. Small cells are currently a focus of research leading to new challenges for the backhaul network because of their dense deployment. The forecasted rise in traffic demand of mobile users has to be met with new network architectures. While the trend of reducing the cell area coverage improves the spectrum spatial efficiency by allowing the carrier frequency reusing, at the same time it imposes challenges in cell edge intelligence and distributed cell control in order to avoid degrading the spectrum temporal efficiency due to the small cell high-density area. Two main aspects may be worth to analyse here are:  the C-RAN approach, having an impact on data traffic and latency that has to be supported inside the Transport network  the maximum connection length that has to be supported having impact on transceiver and antenna performances.
AutoNDA by SimpleDocs
Impact of the second curation step In order to further evidentiate the behavior of Holistsic IAA, we use it to quantify the impact of the corpus-level curation step. This step was performed per-language after the usual document- level curation step was accomplished. The data was sorted per-label and the master curators looked at the overall coherence of the annotated text-span label pairs, the context of the spans was also pro- vided. This step lead to several corrections and is understood to have boosted the overall coherence of the dataset, and should be reflected with a higher o value for the corpus. In Table 5 we consider the agreement as mea- sured by Holistic IAA after step 1 and 2 of the curation by considering the 4 most active cura- tors: ai and si denote respectively the agreement percentage between annotators and the support at step i. For step 2, the o value is higher, and the average IAA is 1.6 pts higher, while the average intra-annotator agreement (self-agreement) is 3.5 pts higher. This demonstrates that Holistic IAA is able to capture and quantify the positive impact of the corpus-level curation. In Table 6 we illustrate the impact of exclud- ing Loaded Language (MW:LL) and Name Calling (AR:NCL) from the dataset as these labels constitute nearly half of the annotations and are frequently confused with each other by annotators in terms of absolute number (but not in proportion) as shown in Figure 1 and Table 1. We observe that the agree- ment between annotators can be label specific. In Figure 8 we consider the whole curated dataset and measure the o value between pairs of languages. The columns ai report the value after step 1 and 2 considering the whole range of la- bels, while the columns a′i exclude the two labels MW:LL and AR:NCL. Doing so gives us an under- standing of the agreement for the lower populated labels. Please note that all the Attacks on Repu- tation (AR:*) and Manipulative Wordings (MW:*) were excluded from the second step of the curation due to time constraints - except for DE and PL. The impact of the second curation step is almost always positive for all pairs of languages, except notably for one language for which the related o values de- teriorate and which drags down the intra-language coherence score. cur1 cur2 a1 s1 a2 s2 A A 0.597 193778 0.603 177604 A B 0.5 57351 0.517 54503 A C 0.586 45694 0.595 183937 A D 0.544 51327 0.548 123539 B B 0.49 10319 0.523 10210 B C 0.451 8575 0.434 29189 B D 0.61 11688 0.625 27113 C C 0.597 3185...
Impact of the. Merger on corporate social responsibility The merger will have no impact on the corporate social responsibility policy of CaixaBank.
Impact of the variance bound In this subsection we keep the insured’s initial wealth unchanged and analyze the impact of the variance bound on her demand for insurance. Consider two variance bounds with 0 < ν1 < ν2 < var[X] and denote the corresponding optimal indemnity functions by I1∗ and I2∗ and the parameters by β1∗ and β2∗, respectively. Thus, the insurer’s risk exposures, eIi∗ (x) = Ii∗(x) − E[Ii∗(X)], i = 1, 2, satisfy Ur(w0 − x + eIi∗ (x)) − 2βi∗eIi∗ (x) − E[Ur(w0 − X + eIi∗ (X))] = 0 (4.4) and E[eI∗ (X)] = 0 and E[(eI∗ (X)) ] = var[eI∗ (X)] = νi. (4.5) The following theorem illustrates how the insurer’s risk exposure responds to the change in the variance bound.
Impact of the parties’ incentives on the feasibility, private value, and public value of settlement Armed with this understanding of the parties’ incentives, we are ready to explore the circumstances under which settlements are feasible, and then to assess whether feasible settlements will necessarily inure to the benefit of the customer. In what follows, for simplicity, we will focus on potential agreements under which the licensee (alleged infringer) pays a running royalty to the licensor (patentee) and exclude complications such as lump sum payments (in either direction), cross-licenses, and other trappings that may well come into play in real life. The condition under which a given license agreement is feasible is simple enough to state: an agreement is feasible if it offers the litigants—patentee and alleged infringer alike—an alternative that each prefers to continued litigation. We assume, moreover, that a party will prefer the settlement agreement if that party’s total profits under the agreement are no lower than the mathematical expectation (the probability-weighted average) of the value of litigation.17 Let P represent the probability that the patentee prevails in the lawsuit, let PROFITDE represent the entrant’s profit under a pure duopoly (i.e., the situation in which the parties do not settle and the patentee loses the lawsuit), let PROFITDP represent incumbent patentee’s profit under the same scenario, and let PROFITMP represent the patentee’s profit in the event that it wins the lawsuit and retains its patent monopoly. Finally, let R

Related to Impact of the

  • ACCIDENT PREVENTION T h i s p r o v i s i o n i s applicable to all Federal-aid construction contracts and to all related subcontracts.

  • Data Portability Operator shall, at the request of the LEA, make Data available including Pupil Generated Content in a readily accessible format.

  • Fraud, Waste, and Abuse Contractor understands that HHS does not tolerate any type of fraud, waste, or abuse. Violations of law, agency policies, or standards of ethical conduct will be investigated, and appropriate actions will be taken. Pursuant to Texas Government Code, Section 321.022, if the administrative head of a department or entity that is subject to audit by the state auditor has reasonable cause to believe that money received from the state by the department or entity or by a client or contractor of the department or entity may have been lost, misappropriated, or misused, or that other fraudulent or unlawful conduct has occurred in relation to the operation of the department or entity, the administrative head shall report the reason and basis for the belief to the Texas State Auditor’s Office (SAO). All employees or contractors who have reasonable cause to believe that fraud, waste, or abuse has occurred (including misconduct by any HHS employee, Grantee officer, agent, employee, or subcontractor that would constitute fraud, waste, or abuse) are required to immediately report the questioned activity to the Health and Human Services Commission's Office of Inspector General. Contractor agrees to comply with all applicable laws, rules, regulations, and System Agency policies regarding fraud, waste, and abuse including, but not limited to, HHS Circular C-027. A report to the SAO must be made through one of the following avenues: ● SAO Toll Free Hotline: 1-800-TX-AUDIT ● SAO website: xxxx://xxx.xxxxx.xxxxx.xx.xx/ All reports made to the OIG must be made through one of the following avenues: ● OIG Toll Free Hotline 0-000-000-0000 ● OIG Website: XxxxxxXxxxxXxxxx.xxx ● Internal Affairs Email: XxxxxxxxXxxxxxxXxxxxxxx@xxxx.xxxxx.xx.xx ● OIG Hotline Email: XXXXxxxxXxxxxxx@xxxx.xxxxx.xx.xx. ● OIG Mailing Address: Office of Inspector General Attn: Fraud Hotline MC 1300 P.O. Box 85200 Austin, Texas 78708-5200

  • Emergency Medical Condition A medical condition manifesting itself by acute symptoms of sufficient severity (including severe pain) such that a prudent layperson, who possesses an average knowledge of health and medicine, could reasonably expect the absence of immediate medical attention to result in any of the following: (1) placing the health of the individual (or with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy; (2) serious impairment to body functions; or (3) serious dysfunction of any body organ or part.

  • Fire Safety 9.5.1 Residents found in violation of the following fire safety stipulations not only put themselves at risk but also jeopardizes the safety of the entire community.

  • COMPLIANCE WITH HEALTH, SAFETY, AND ENVIRONMENTAL REGULATIONS The Contractor, it’s Subcontractors, and their respective employees, shall comply fully with all applicable federal, state, and local health, safety, and environmental laws, ordinances, rules and regulations in the performance of the services, including but not limited to those promulgated by the City and by the Occupational Safety and Health Administration (OSHA). In case of conflict, the most stringent safety requirement shall govern. The Contractor shall indemnify and hold the City harmless from and against all claims, demands, suits, actions, judgments, fines, penalties and liability of every kind arising from the breach of the Contractor’s obligations under this paragraph.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • OMB Standards Unless specified otherwise within this agreement, the Subrecipient shall procure all materials, property, or services in accordance with the requirements of 24 CFR 84.40−48.

  • Public safety compliance The Hirer shall comply with all conditions and regulations made in respect of the premises by the Fire Authority, Local Authority, the Licensing Authority or otherwise, particularly in connection with any event which constitutes regulated entertainment, at which alcohol is sold or provided or which is attended by children.

  • Anti-Money Laundering/International Trade Law Compliance No Covered Entity is a Sanctioned Person. No Covered Entity, either in its own right or through any third party, (i) has any of its assets in a Sanctioned Country or in the possession, custody or control of a Sanctioned Person in violation of any Anti-Terrorism Law; (ii) does business in or with, or derives any of its income from investments in or transactions with, any Sanctioned Country or Sanctioned Person in violation of any Anti-Terrorism Law; or (iii) engages in any dealings or transactions prohibited by any Anti-Terrorism Law.

Time is Money Join Law Insider Premium to draft better contracts faster.